Table_8_The add-on effect of Shufeng Jiedu capsule for treating COVID-19: A systematic review and meta-analysis.DOCX

IntroductionShufeng Jiedu capsule (SFJD) is a commonly used Chinese patent medicine in China. Some studies have reported that SFJD has therapeutic effects in patients diagnosed with COVID-19. This systematic review aimed to critically evaluate the efficacy and safety of SFJD combined with western medicine (WM) for treating COVID-19.MethodsA literature search by using WHO COVID-19 database, PubMed, Embase, Cochrane Library, the Web of Science, CKNI, Wanfang, VIP, SinoMed, and clinical trial registries was conducted, up to 1 August 2022. Randomized controlled trials (RCTs), non-RCTs, cohort studies and case series of SFJD combined with WM for COVID-19 were included. Literature screening, data extraction, and quality assessment were performed independently by two reviewers in line with the same criteria. We used the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) to assess the certainty of evidence. Meta-analyses were performed with Revman 5.3 if possible. The descriptive analysis was conducted when the studies could not be meta-analyzed.ResultsTotally 10 studies with 1,083 patients were included. Their methodological quality were moderate. The results demonstrated that compared to WM group, SFJD + WM group remarkably increased the nucleic acid negative conversion rate (RR = 1.40, 95%CI: 1.07–1.84), total effective rate (RR = 1.18, 95%CI: 1.07–1.31), cure rate (RR = 4.06, 95%CI: 2.19–7.53), and the chest CT improvement rate (RR = 1.19, 95%CI: 1.08–1.31), shorten nucleic acid negative conversion time (MD = −0.70, 95%CI: −1.14 to −0.26), reduced the clinical symptom disappearance time (fever, diarrhea, cough, fatigue, pharyngalgia, nasal congestion, and rhinorrhea), as well as improved the levels of laboratory outcomes (CRP, IL-6, Lym, and Neu). Additionally, the incidence of adverse reactions did not exhibit any statistically significant difference between SFJD + WM group and WM group.ConclusionSFJD combined with WM seems more effective than WM alone for the treatment of COVID-19. However, more well-designed RCTs still are warranted.Systematic review registration[https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42022306307].

简介：疏风解毒胶囊（SFJD）是我国常用的一种中药。部分研究指出，SFJD对于确诊为COVID-19的病患具有治疗作用。本研究旨在对SFJD联合西医（WM）治疗COVID-19的疗效与安全性进行批判性评估。方法：通过WHO COVID-19数据库、PubMed、Embase、Cochrane图书馆、Web of Science、CKNI、万方、VIP、SinoMed以及临床试验注册库进行文献检索，截止至2022年8月1日。纳入了随机对照试验（RCTs）、非随机对照试验、队列研究和SFJD联合WM治疗COVID-19的病例系列研究。文献筛选、数据提取和质量评估由两位评审员独立进行，遵循相同的标准。使用 GRADE（推荐评估、发展、评价）系统对证据的确定性进行评估。在可能的情况下，使用Revman 5.3进行荟萃分析。当研究无法进行荟萃分析时，进行描述性分析。结果：共纳入10项研究，涉及1083名患者，其方法论质量中等。结果显示，与WM组相比，SFJD + WM组显著提高了核酸转阴率（相对风险比RR = 1.40，95%置信区间：1.07–1.84）、总有效率（RR = 1.18，95%置信区间：1.07–1.31）、治愈率（RR = 4.06，95%置信区间：2.19–7.53）和胸部CT改善率（RR = 1.19，95%置信区间：1.08–1.31），缩短了核酸转阴时间（平均差异MD = −0.70，95%置信区间：−1.14至−0.26），减少了临床症状消失时间（发热、腹泻、咳嗽、疲劳、咽痛、鼻塞和流涕），并改善了实验室指标水平（C反应蛋白、IL-6、淋巴细胞和神经元）。此外，SFJD + WM组和WM组的不良反应发生率在统计学上无显著差异。结论：SFJD联合WM治疗COVID-19的效果似乎优于单独使用WM。然而，仍需更多设计良好的RCTs。系统评价注册[https://www.crd.york.ac.uk/PROSPERO/]，标识符[CRD42022306307]。